Cadila Pharmaceuticals Ltd.’s Chairman and Managing Director, Dr Rajiv Modi, announced the launch of a new drug aimed at making lung cancer treatment much more affordable. The drug named Mycidac-C is competitively priced at Rs 40,000 for a 10-course injection. It is a non small cell cancer drug. Being almost 1/10th of the price of existing therapies, it is much cheaper than other similar drugs in the market, which could help take the drug global. However, its first target is the Indian market where there are over 50,000 new cases of lung cancer every year and treatment currently is very expensive for the same. Moving ahead, Cadila aims to launch the drug overseas and is looking for suitable oncology partners in global markets like Latin America, Southeast Asia, Africa, Saudi Arabia, United States of America and Europe as well.
Watch the full video here.
